Weekly Analysts’ Ratings Changes for VolitionRx (VNRX)

VolitionRx (NYSE: VNRX) has recently received a number of price target changes and ratings updates:

• 3/4/2025 – VolitionRx is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 3/4/2025 – VolitionRx had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.
• 2/24/2025 – VolitionRx is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 2/16/2025 – VolitionRx is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 2/8/2025 – VolitionRx is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 2/6/2025 – VolitionRx had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.
• 1/31/2025 – VolitionRx is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 1/29/2025 – VolitionRx had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.
• 1/23/2025 – VolitionRx is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 1/15/2025 – VolitionRx is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 1/8/2025 – VolitionRx had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.
• 1/7/2025 – VolitionRx is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.

VolitionRx Stock Performance

NYSE:VNRX traded up $0.03 on Thursday, hitting $0.61. The stock had a trading volume of 57,738 shares, compared to its average volume of 104,852. VolitionRx Limited has a 1 year low of $0.43 and a 1 year high of $1.10. The firm’s fifty day simple moving average is $0.61 and its two-hundred day simple moving average is $0.65. The stock has a market cap of $56.62 million, a P/E ratio of -1.70 and a beta of 1.20.

Insider Buying and Selling

In other news, Director Guy Archibald Innes purchased 174,764 shares of the business’s stock in a transaction dated Monday, December 9th. The stock was bought at an average price of $0.57 per share, for a total transaction of $99,615.48. Following the purchase, the director now owns 617,085 shares of the company’s stock, valued at $351,738.45. The trade was a 39.51 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Cameron John Reynolds acquired 139,811 shares of the stock in a transaction that occurred on Monday, December 9th. The stock was purchased at an average price of $0.57 per share, for a total transaction of $79,692.27. Following the completion of the purchase, the chief executive officer now directly owns 2,117,404 shares in the company, valued at $1,206,920.28. This trade represents a 7.07 % increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 358,266 shares of company stock worth $204,212. Insiders own 12.80% of the company’s stock.

Institutional Trading of VolitionRx

Institutional investors and hedge funds have recently made changes to their positions in the stock. Two Sigma Securities LLC purchased a new stake in VolitionRx during the fourth quarter valued at about $29,000. Millennium Management LLC purchased a new position in shares of VolitionRx during the 4th quarter valued at about $36,000. Northern Trust Corp lifted its position in VolitionRx by 32.0% in the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock worth $71,000 after buying an additional 28,579 shares during the last quarter. Geode Capital Management LLC grew its position in VolitionRx by 15.1% during the third quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock valued at $439,000 after acquiring an additional 95,900 shares during the last quarter. Finally, Lagoda Investment Management L.P. grew its position in VolitionRx by 24.3% during the fourth quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock valued at $4,546,000 after acquiring an additional 1,481,000 shares during the last quarter. Hedge funds and other institutional investors own 8.09% of the company’s stock.

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.